HK inno.N r, up 17% in about a year after the launch. HK inno.N sold alone, no commission share, profitability improved as more sold

Expiration of the joint sales contract with Chong Kun Dang at the end of the year, will it affect renewal negotiations?
HK inno.N K-Cab OD tablets accounted for 17.0% of the total prescription performance of this product. HK inno.N's K-Cab joint sales contract with Chong Kun Dang is about to expire at the end of this year. The increase in the proportion of prescriptions for OD tab, sold exclusively by HK inno.N, is expected to act as a variable in determining conditions such as the sales commission rate in the process of contract renewal negotiations betwe